Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook

By Reuters News04:01 (UTC), 5 November 2026 Updated

** Shares of Australia's Neuren Pharmaceuticals NEU.AX climb as much as 17.7% to A$23.3, marking their biggest intraday pct gain since June 29

** Shares hit their highest level since August 20

** Biopharmaceutical co upgrades 2026 income forecast from trofinetide (DAYBUE) to $91 million-$93 million from $53 million-$56 million. Trofinetide is used for the treatment of Rett Syndrome, a genetic neurological and developmental disorder

** Co says partner Acadia Pharmaceuticals raised full-year global sales forecast for DAYBUE to $505 million-$520 million from $480 million-$510 million

** Adds Q3 DAYBUE net sales rose 39% year-on-year to $140 million

** Adds Japan results of Phase 3 trial of DAYBUE support a planned regulatory filing in 2027 and potential launch in 2028

** More than 790,000 shares change hands, about 2.3x the 30-day average

** YTD, stock up 23.6%